Placebo-Controlled, Randomized, Parallel Group, Multiple-Dose Study to Evaluate the Effects of CP-481,715 on Clinical Response and Cellular Infiltration Following Contact Allergen Challenge to the Skin of Nickel Allergic Subjects.
Latest Information Update: 17 Sep 2014
At a glance
- Drugs CP 481715 (Primary)
- Indications Hypersensitivity
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Pfizer
- 17 Sep 2014 New trial record